News

Precision Neuroscience Acquires U.S. Manufacturing Facility and Receives FDA Breakthrough Device Designation

The purchase allows the brain–computer interface company to oversee the end-to-end fabrication of its microelectrode array while iterating quickly on…

10 months ago

Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference

MIAMI, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently…

10 months ago

Intelligent Bio Solutions Adds Logistics Firm to Fingerprint Drug Screening Portfolio and Completes Major Milestone with Existing Client

VKVP Haulage adopts Fingerprint Drug Screening System to help drive proactive drug testing policy Auctus Management Group successfully completes 25,000…

10 months ago

NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum

TORONTO and HAIFA, Israel, Oct. 05, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”…

10 months ago

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology…

10 months ago

SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023

DENVER, Oct. 05, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions…

10 months ago

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler – REDWOOD CITY, Calif.,…

10 months ago

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

TN-201 is the First Gene Therapy for the Leading Genetic Cause of HCM to be Assessed in Humans; Adds Working…

10 months ago